The Medicines Company (NASDAQ:MDCO) EVP Christopher T. Cox bought 50,300 shares of the business’s stock in a transaction on Friday, November 16th. The stock was bought at an average cost of $19.73 per share, for a total transaction of $992,419.00. Following the purchase, the executive vice president now directly owns 60,308 shares of the company’s stock, valued at approximately $1,189,876.84. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

NASDAQ MDCO opened at $20.65 on Tuesday. The stock has a market cap of $1.48 billion, a PE ratio of -2.46 and a beta of 1.06. The company has a current ratio of 2.41, a quick ratio of 2.40 and a debt-to-equity ratio of 31.23. The Medicines Company has a one year low of $19.55 and a one year high of $41.57.

The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.13). The business had revenue of ($3.30) million for the quarter, compared to analyst estimates of $1.88 million. The Medicines had a negative return on equity of 1,477.75% and a negative net margin of 668.93%. The company’s revenue for the quarter was down 141.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.19) EPS. Research analysts anticipate that The Medicines Company will post -2.91 earnings per share for the current fiscal year.

Several equities analysts have weighed in on the company. Cowen set a $46.00 target price on The Medicines and gave the company a “buy” rating in a research note on Sunday, November 11th. Zacks Investment Research lowered The Medicines from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. Oppenheimer set a $50.00 price target on The Medicines and gave the stock a “buy” rating in a research report on Friday, November 9th. BidaskClub lowered The Medicines from a “buy” rating to a “hold” rating in a research report on Saturday, August 4th. Finally, Citigroup raised their price target on The Medicines from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, August 20th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The Medicines currently has an average rating of “Buy” and an average target price of $52.75.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDCO. Teachers Advisors LLC grew its holdings in shares of The Medicines by 1.2% during the third quarter. Teachers Advisors LLC now owns 257,633 shares of the company’s stock worth $7,706,000 after buying an additional 3,164 shares in the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in shares of The Medicines during the third quarter worth about $2,919,000. MetLife Investment Advisors LLC grew its holdings in shares of The Medicines by 55.0% during the third quarter. MetLife Investment Advisors LLC now owns 49,654 shares of the company’s stock worth $1,485,000 after buying an additional 17,616 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of The Medicines during the third quarter worth about $818,000. Finally, Bailard Inc. grew its holdings in shares of The Medicines by 115.4% during the third quarter. Bailard Inc. now owns 70,000 shares of the company’s stock worth $2,094,000 after buying an additional 37,500 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “The Medicines Company (MDCO) EVP Christopher T. Cox Buys 50,300 Shares” was first posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2018/11/20/the-medicines-company-mdco-evp-christopher-t-cox-buys-50300-shares.html.

About The Medicines

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

Further Reading: Cost of Equity

Insider Buying and Selling by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.